


**Al-Quds University**

**Deanship of Graduate Studies**



**Beliefs about Cholesterol Lowering Drugs and Medication  
Adherence Among Palestinian Adults with Dyslipidemia  
in Ramallah and Bethlehem areas of the West Bank**

**Jihad Khalil Ahmad Shakarna**

**M.Sc. Thesis**

**Jerusalem, Palestine**

**1441/2019**

**Beliefs about Cholesterol Lowering Drugs and Medication  
Adherence Among Palestinian Adults with Dyslipidemia in  
Ramallah and Bethlehem areas of the West Bank**

**Prepared by:**

**Jihad Khalil Ahmad Shakarna**

**B.Sc.: Pharmacy from Al-Quds University, Abu- Dis**


**Supervisor: Dr. Hussein Hallak**

**This thesis is submitted in partial fulfillment of the  
requirements for the degree of Master of Pharmaceutical  
science in Pharmacy Department.**

**Al-Quds University**

**1441/2019**

Al-Quds University  
Deanship of Graduate studies  
Pharmaceutical Science Program



### Thesis Approval

**Beliefs about Cholesterol Lowering Drugs and medication Adherence among  
Palestinian Adults with Dyslipidemia in Ramallah and Bethlehem areas of  
West Bank.**

**Prepared by: Jihad Khalil Shakarna.**

**Registration No: 21512575**

**Supervisor: Dr. Hussein Hallak**

**Master thesis Submitted and accepted, Date: 7/12/2019**

**The names and signatures of the examining committee members are as  
follows:**

**1-Head of committee: Dr. Hussein Hallak      signature: ..........**

**2-Internal examiner: Dr. Maher Khmour      signature: ..........**

**3-External Examiner: Dr. Samah Al-Jabi      signature: ..........**

**Jerusalem – Palestine**

**1441/ 2019**

## **Dedication**

I dedicate my graduation project to those who harvested thorns from my way to pave the path of science to the great hearts to my parents.

To my lovely husband for his endless support and encouragement. To my beloved children Khaled and Mesk who give me the power and inspiration to keep on.

Also to my sisters and brothers, who gave me all the support to complete my research step by step. Without their unfailing support and help this work would not have been possible.

## Declaration

I certify that this thesis submitted for the degree of Master, is the result of my own research, except where otherwise acknowledged, and that this study (or any part of the same) has not been submitted for a higher degree to any other university or institution.

Signed: Jihad Shakarna

Jihad Khalil Shakarna

Date: 14/12/2019

## **Acknowledgements**

First of all, I thank Allah for giving me strength and ability to complete this project.

Special thanks for my professors for their guidance, encouragement, and help through this study.

Many thanks also for all workers at health clinics at Ramallah and Bethlehem, my thanks for the participants who willingly accepted to share for the purpose of this study.

Finally, an honorable mention goes to my family for their understandings and supports for me in completing this project, the product of this project would not be possible without all of them.

## Table Contents

### Table of Contents

V.....	Dedication
i.....	Declaration
ii.....	Acknowledgements
iii.....	Table Contents
v.....	List of Tables
vi.....	List of Figures
vii.....	List of Abbreviations
1.....	<b>Chapter one</b>
1.....	Introduction
1.....	1.1. Dyslipidemia
3.....	1.2 Types of dyslipidemia:
4.....	1.3 Classification of Dyslipidemia:
5.....	1.4 Causes of Dyslipidemia
5.....	1.5 Symptoms and diagnosis:
6.....	1.6 Adherence
9.....	1.8 Prevalence of dyslipidemia
11.....	1.9 Problem statement:
11.....	1.10 General Objectives :
12.....	1.11 Specific objectives:
13.....	<b>Chapter Two</b>
13.....	Literature review
13.....	2.1 Literature review:

16	2.2 Significance of study :
17	<b>Chapter Three</b>
17	Methods and Materials
17	3.1 Study design
17	3.2 Study setting
17	3.3 Study Participants
18	3.4 Sampling procedure and sample size calculation
18	3.5 Inclusion and exclusion criteria
18	3.6 Instruments and data collection form
20	3.7 Ethical approval
21	3.8 Pilot study
21	3.9 Statistical analysis
22	<b>Chapter Four</b>
22	4.1. Patient characteristics
22	4.2 Non-adherence behaviors
25	4.3 Beliefs concerning medicines
27	4.4 Association of beliefs with other factors
30	Chapter five
30	Discussion
35	<b>Chapter Six</b>
35	Conclusion
35	6.1 Strength of our study:
36	6.2 Recommendation and limitations
37	6.3 Conclusion
38	References :-
43	Appendices A:
56	الملخص:



## Tables

<b>Table</b>	<b>Content</b>	<b>Page</b>
1.1	Classification of Dyslipidemia	4
4.2	Patient characteristics and the results of the univariate analysis of factors with potential impact on medication adherence	23
4.3	Adherence and non-Adherence Rates, Likely Causes of non-Adherence among Study Participants (n= 185).	23
4.4	Adherent and non-adherent patients' beliefs about medicines scores	28
4.5	Associations of study variables with Beliefs about Medicines Necessity Specific scores	28
4.6	Associations of study variables with Beliefs about Medicines Concern Specific scores	29
4.7	Multiple regression analysis for variables predicting non-adherence	29

## List of Figures

<b>Figure</b>	<b>Content</b>	<b>Page</b>
1.1	Five dimensions of adherence	9
4.2	Percentage of respondents agreeing/strongly agreeing with Beliefs about Medicines Questionnaire statements (Necessity-statements)	25
4.3	Percentage of respondents agreeing/strongly agreeing with Beliefs about Medicines Questionnaire statements (Concerns -statements)	26
4.4	Framework of patients' attitudes and beliefs about medication	27

## List of Abbreviations

<b>Abbreviation</b>	<b>Explanation</b>
BMQ	Brief medication questionnaire
CHD	Coronary heart disease
CVD	Cardiovascular disease
HDL	High density lipoprotein
HIV	Human immune deficiency
IRB	Institutional review boards
LDL	Low density lipoprotein
MESA	Multi ethnic study of atherosclerosis
MMAS-4	Morisky medication adherence scale four items
MS	Metabolic syndrome
NCD	Necessity concern differential
NCDs	Non-Communicable Diseases
NCEP	National cholesterol education panels
NCF	Necessity concern framework
NHANES	National health and nutr Trying to provide the medicine permanently to patients in private health centers that it needs permanent and uninterrupted treatment for these medicines situation examination survey
SD	Standard deviation
SPSS	Statistical package for social sciences
SRM	Self-regulatory model
TC	Total Cholesterol
TG	Triglyceride
WHO	World health organization

## **Abstract**

### **Background:**

Lipid-lowering drugs are widely underused, despite strong evidence indicating they improve cardiovascular end points. Poor patient adherence to a medication regimen can affect the success of lipid-lowering treatment.

### **Objectives:**

The aim of the present study was to assess the level of medication adherence among hypelipidemic patient's, patient's beliefs about medicines and explore the relationship between medication adherence and medicines beliefs and other demographic and clinical variables in the study participants.

### **Methods:**

The study was a cross sectional design conducted between Jan 2019 and July 2019 to evaluate the influence of beliefs about medicines, demographic and clinical factors on adherence to cholesterol lowering drugs among Palestinians. This study was carried out at middle governmental primary healthcare clinics in Ramallah and Bethlehem cities. The disease specific tool is Morisky and beliefs about medicine questionnaires (BMQ).

Adherence was measured using self-reported four-item Morisky Medication Adherence Scale (MMAS-4) which measures the medication adherence with questions 1-4 having dichotomous responses (No =0 score and Yes = 1 score). The results were analyzed using Statistical Package for Social Sciences (SPSS) program version 21 Multiple linear regression analysis was performed to determine the most important variables related to adherence in dyslipidemic patient.

## **Results:**

Of the 220 patients approached, a total of 185 patients agreed to participate in the study with a response rate of (84.1%). Of them, 106 (57.3) were men. Almost half of the participants 88 (46.5%) were  $\geq 56$  years. According to the MMAS-4 scale, medication non-adherence was high (47.6%). The majority of the participants (65.5%) believed in the necessity of their treatment for maintaining their good health. Mean necessity score of 17.3 (S.D. 3.7) was significantly greater than mean concerns score of 14.0 (3.5);  $P < 0.001$ ). Multivariate regression demonstrated that 4 variables remain significant and associated with non-adherence; illiterate (OR= 2.52; CI: 0.9 – 4.3;  $P = 0.03$ ), polypharmacy (OR= 3.18; CI: 1.9-5.7;  $P = 0.007$ ), having comorbidity (OR= 3.10; CI: 2.2-4.6;  $P = 0.005$ ) and having concerns about side effects (OR= 2.89; CI: 1.1-4.6,  $P = 0.04$ ) were most likely non-adhere to their medications.

**Conclusion:**

Non-adherence among patients taking lipid lowering agents was high. Most people with hyperlipidemia have positive beliefs about the necessity of their medication. However, levels of concern are also high. Physicians should identify and target high risk patients and individualize their treatment plan in order to achieve adequate control of hyperlipidemia.

**Key words:**

Hyperlipidemia, Cholesterol, Statin, Adherence, Beliefs, -Palestine, WHO, MMSA-4, BMQ, CVD, CHD.

# Chapter one

---

## Introduction

### 1.1. Dyslipidemia

When lipoproteins are overproduced or deficient, the result is a lipoprotein metabolism disorder known as dyslipidemia. Elevated total cholesterol is one of the culprits of dyslipidemia. Cholesterol is a fat protein that is produced by the liver and is necessary to maintain healthy cell membranes, brain function, hormone production, and vitamin storage.

The two forms of cholesterol are high-density lipoprotein (HDL) and low-density lipoprotein (LDL). As their names suggest, both LDL and HDL are lipoproteins that comprise a combination of a lipid and a protein. The lipid portion is bound to proteins, for the cholesterol molecules to move through the blood.

LDL and HDL are unique in their function. LDL it is sometimes called "bad cholesterol," because high LDL levels cause risk factor for the CAD. In contrast, HDL is called as the "good one," because it transfer the cholesterol back to liver, which is how cholesterol is removed.

A diagnosis of dyslipidemia occurs when the total cholesterol (TC) level is above the normal value, or when LDL is generated or eat diary or bad foods [1]. A hyperlipidemia patient may show elevated levels of either LDL and TG or both. Triglycerides are a type of fat found in the blood. TG are associated with coronary heart disease.

Metabolic syndrome (MS) is a condition when a patient has a variety of medical disorders that combined show an increased risk of developing cardiovascular disease (CVD). Studies in Middle East showed that MS affects approximately one in four people, and its incidence increases with age. Due to reports showing increase percentages of MS and its main cardiovascular risk factors (15-60%) among Middle Eastern populations, there is a need for national and international programs that counter obesity, hypertension, and especially dyslipidemia. Ultimately, it is crucial to focus on early prevention and control [2].

The treatment of dyslipidemia is clearly prevent primary and secondary heart diseases. However, in Europe and the USA, cross-sectional surveys examining factors associated with chronic heart disease show that treatment of dyslipidemia remains inadequate. Consequently, more studies are necessary to evaluate the present level of undertreated dyslipidemia , which occurs when a patient receives a lipid-lowering treatment but still has TC and/or LDL-C levels that are uncontrolled, and why some patients on suboptimal therapy which consequently prone to CVD. [3-6]. Thus, the aim of this study was to examine the effect of dyslipidemia on the daily life of patients by measuring their compliance indices and their adherence to medication.